Urtica Sp. z o.o. secures contract for Pharmaceutical products - Purchase and delivery of the Mavacamten medicinal product as part of the implementation of Drug Program B162 - TREATMENT OF PATIENTS WITH CARDIOMYOPATHY - 1 product package

Poland, Sept. 3 -- Poland based Urtica Sp. z o.o. has secured contract from UNIWERSYTECKI SZPITAL KLINICZNY W POZNANIU for Pharmaceutical products - Purchase and delivery of the Mavacamten medicinal product as part of the implementation of Drug Program B162 - TREATMENT OF PATIENTS WITH CARDIOMYOPATHY - 1 product package . The value of the contract is worth 987999.24 PLN .

Published by HT Digital Content Services with permission from Pivotal Sources....